Academic Journal
COVID-19 Vaccination Refusal and Non-Uptake Among People Living with HIV in the United States.
| Τίτλος: | COVID-19 Vaccination Refusal and Non-Uptake Among People Living with HIV in the United States. |
|---|---|
| Συγγραφείς: | Khubchandani J; College of Health, Education, and Social Transformation, New Mexico State University, Las Cruces, NM, 88003, USA. jagdish@nmsu.edu., Prabhu N; Burrell College of Osteopathic Medicine, Las Cruces, NM, 88001, USA., Craig K; Burrell College of Osteopathic Medicine, Las Cruces, NM, 88001, USA., Wiblishauser M; College of Education and Health Professions, Texas A&M University-Victoria, Victoria, TX, 77901, USA., Mustapha T; School of Public Health and Information Sciences, University of Louisville, Louisville, KY, 40202, USA., Srejon RR; School of Public Health, University of Nevada Las Vegas, Las Vegas, NV, 89154, USA., Batra K; Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV, 89154, USA. |
| Πηγή: | Journal of community health [J Community Health] 2026 Oct; Vol. 51 (5), pp. 896-904. Date of Electronic Publication: 2026 Jul 23. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer Country of Publication: Netherlands NLM ID: 7600747 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-3610 (Electronic) Linking ISSN: 00945145 NLM ISO Abbreviation: J Community Health Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Springer Original Publication: New York, Human Sciences Press. |
| Ιατρικοί όροι (MeSH): | HIV Infections*/psychology , HIV Infections*/epidemiology , COVID-19 Vaccines*/administration & dosage , COVID-19*/prevention & control , COVID-19*/epidemiology , Vaccination Refusal*/statistics & numerical data , Vaccination Refusal*/psychology , Vaccination Hesitancy*/statistics & numerical data, United States/epidemiology ; Humans ; Female ; Male ; Unvaccinated Persons |
| Περίληψη: | More than a million individuals in the United States are living with HIV and constitute a particularly vulnerable group for morbidity and mortality associated with COVID-19. Despite the early availability and prioritization of this group for COVID-19 vaccination, notable levels of vaccine refusal and non-uptake have been reported among this group. This scoping review aimed to investigate the nature and extent of COVID-19 vaccine refusal and non-uptake among people living with HIV (PLWH) in the USA. A comprehensive literature search was performed utilizing multiple scholarly databases for studies published between December 2020 and May 2026 that reported on COVID-19 vaccine refusal or non-uptake rates among PLWH in the USA. Data extraction focused on sample size, refusal/non-uptake rates, reasons for refusal, and vaccination enablers. A total of 27 studies were included, encompassing 185,430 PLWH from various settings across the U.S. and the COVID-19 vaccination refusal and non-uptake rates varied from 3.8% to 57.9% [average across all studies=21.0% (95% CI=16.2-26.2%)]. Major barriers identified included medical mistrust, apprehensions regarding vaccine safety and side effects, misinformation, structural issues such as poverty and housing instability, and sociodemographic factors (e.g., sexual/ethnic minority status, lower income or education). Conversely, enablers of vaccination included older age, male gender, White race, active engagement in HIV care, previous vaccination history, recommendations from trusted providers, and higher perceived infection risk or belief in vaccination. The refusal and non-uptake rates for COVID-19 vaccines among PLWH in the USA are considerable and influenced by multiple factors. Interventions should focus on addressing systemic mistrust and psychosocial or structural obstacles while utilizing the existing HIV care framework to increase vaccination rates in this population. (© 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Competing Interests: | Declarations. Conflict of interest: Authors have no conflicts of interests to declare. Ethical Approval: This is a review paper, and no human subjects were involved. |
| References: | J Acquir Immune Defic Syndr. 2024 Jun 1;96(2):106-113. (PMID: 38567932) Open Forum Infect Dis. 2021 Mar 26;8(6):ofab154. (PMID: 34621912) Trop Med Infect Dis. 2022 Feb 03;7(2):. (PMID: 35202217) Clin Infect Dis. 2022 Aug 24;75(1):e726-e733. (PMID: 35024825) Emerg Infect Dis. 2024 Jul;30(7):1326-1334. (PMID: 38916545) AIDS Behav. 2022 Jul;26(7):2256-2265. (PMID: 35024992) Prev Med Rep. 2023 Jun 24;35:102300. (PMID: 37455759) J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):124-134. (PMID: 37368934) J Dent Sci. 2022 Apr;17(2):1043-1047. (PMID: 35070133) J Epidemiol Glob Health. 2025 Aug 14;15(1):106. (PMID: 40810755) AIDS Care. 2021 Dec;33(12):1569-1576. (PMID: 33486978) Public Health. 2022 Jun;207:31-38. (PMID: 35486981) J Acquir Immune Defic Syndr. 2024 Sep 1;97(1):13-18. (PMID: 39116328) Commun Med (Lond). 2022 Aug 29;2:110. (PMID: 36045906) AIDS Patient Care STDS. 2022 Jan;36(1):34-44. (PMID: 34910884) AIDS Behav. 2022 Jul;26(7):2224-2228. (PMID: 34994913) Public Health Rep. 2022 Sep-Oct;137(5):1031-1040. (PMID: 35848111) Vaccines (Basel). 2021 Mar 24;9(4):. (PMID: 33804808) J Racial Ethn Health Disparities. 2025 Feb;12(1):413-434. (PMID: 38117443) Lancet. 2021 Mar 20;397(10279):1095-1106. (PMID: 33617774) AIDS. 2025 Feb 1;39(2):193-203. (PMID: 39497542) J Acquir Immune Defic Syndr. 2024 Feb 1;95(2):126-132. (PMID: 37988697) Medicine (Baltimore). 2022 Aug 5;101(31):e29907. (PMID: 35945741) JAMA Netw Open. 2024 Jun 3;7(6):e2415220. (PMID: 38842808) Int J Environ Res Public Health. 2023 Jun 08;20(12):. (PMID: 37372669) Brain Behav Immun. 2022 Jan;99:218-222. (PMID: 34673175) BMC Public Health. 2024 Jun 3;24(1):1479. (PMID: 38831275) J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):200-207. (PMID: 33196555) MMWR Morb Mortal Wkly Rep. 2022 Feb 04;71(5):182-184. (PMID: 35113845) Rev Med Virol. 2025 Mar;35(2):e70024. (PMID: 40032549) BMC Public Health. 2025 Oct 1;25(1):3257. (PMID: 41034766) Curr HIV/AIDS Rep. 2022 Oct;19(5):425-432. (PMID: 35930187) J Acquir Immune Defic Syndr. 2024 Apr 1;95(4):329-341. (PMID: 38133577) J Acquir Immune Defic Syndr. 2023 Jun 1;93(2):92-100. (PMID: 36853763) Int J Infect Dis. 2022 Nov;124:212-223. (PMID: 36241168) J Infect Dis. 2022 Feb 15;225(4):603-607. (PMID: 34794178) Vaccines (Basel). 2022 May 11;10(5):. (PMID: 35632514) Viruses. 2021 Sep 22;13(10):. (PMID: 34696319) Folia Microbiol (Praha). 2026 Aug;71(4):933-963. (PMID: 40736939) J Acquir Immune Defic Syndr. 2024 Jan 1;95(1):6-9. (PMID: 37797232) Vaccine. 2024 Jan 25;42(3):645-652. (PMID: 38143200) Front Med (Lausanne). 2022 Jun 30;9:886936. (PMID: 35847816) |
| Grant Information: | 102066 Merck |
| Contributed Indexing: | Keywords: COVID-19; Coronavirus; HIV/AIDS; People living with HIV; Vaccination; Vaccine |
| Substance Nomenclature: | 0 (COVID-19 Vaccines) |
| Entry Date(s): | Date Created: 20260723 Date Completed: 20260926 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1007/s10900-026-01596-5 |
| PMID: | 42493748 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1573-3610 |
|---|---|
| DOI: | 10.1007/s10900-026-01596-5 |